Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Arrowhead Pharmaceuticals reports strong fiscal 2024 results and strategic partnerships

Arrowhead Pharmaceuticals' fiscal 2024 performance was robust, fueled by a game-changing partnership with Sarepta and promising results in the cardiometabolic pipeline.
While facing challenges in differentiation and portfolio management, the company's proactive approach and strong financial position present opportunities for growth and innovation.
Strategic collaborations, ongoing Phase III studies, and plans for debt repayment through partnership cash flows underscore Arrowhead's commitment to value creation and sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 84.
The post Stocks To Watch: Arrowhead Pharma Sees Relative Strength Rating Jump To 84 appeared first on Investor's Business Daily.

Stocks To Watch: Arrowhead Pharma Sees Relative Strength Rating Jump To 84

Arrowhead Pharmaceuticals Long-Term Intact As Shorts Finish Taking Profits

After a stellar 2019, the biotech stock has lost 47% so far in 2020.

Why Arrowhead Pharmaceuticals Shares Dropped 15% in February

Arrowhead Pharmaceuticals: Greed Vs. Fear

Arrowhead Pharmaceuticals: Why JNJ-3989 May Become A First-Line Therapy For Chronic HBV

Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.

Here's Why Arrowhead Pharmaceuticals Fell 33.9% in January

The clinical-stage biotech posted a revenue decline and a widening net loss in Q1. But no one cared.

Arrowhead Pharmaceuticals Q1 Results Didn't Matter -- but Its Pipeline Update Did

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q1 2020 Results - Earnings Call Transcript

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

Sarepta Therapeutics

Sarepta Therapeutics, Inc. And Arrowhead Pharmaceuticals Now Top-Ranked Biotech Stock Buys

Arrowhead Pharmaceuticals, Inc.: A Better Odds-On Capital-Gain Alternative To Alkermes

The biopharma stock received an analyst downgrade.

Here's Why Arrowhead Pharmaceuticals Lost as Much as 14.2% Today

Shares of highly rated biotech company Arrowhead Pharmaceuticals crashed to a two-month low Tuesday after an analyst initiated overage of ARWR stock with an underperform rating.
The post Why This Top-Notch Biotech Stock Just Plunged By Double Digits appeared first on Investor's Business Daily.

Why This Top-Notch Biotech Stock Just Plunged By Double Digits

Amarin Corporation Plc

Intercept Pharma

Flushed with cash, bigger biotech stocks are on the hunt. These 3 smaller drug makers could be the next buyout targets in the new year.

3 Biotech Stocks to Bank on for Buyouts in 2020

The RNAi drug developer tickled investors with promising clinical data.

Here's Why Arrowhead Pharmaceuticals Stock Soared 410% in 2019

Buy Arrowhead Pharmaceuticals Now At Near The Institutional Discount

Dicerna Pharmaceuticals

These two promising RNAi drug developers are trading at hefty premiums going into 2020.

These 2 Stocks Will Fall After the New Year

ArQule

Eidos Therapeutics Inc

Guardant Health Inc

Kodiak Sciences Inc

Medpace Holdings

NeoGenomics

Nevro

Tenet Healthcare

Zoetis

Helping people stricken with illness can be richly rewarding in more ways than one.

These Were the 10 Best Healthcare Stocks of 2019

Blueprint Medicines

Deciphera Pharmaceuticals

They have what deep-pocketed pharmaceutical giants want.

3 Stocks - That Could Be the Next Biotech Buyouts.

Despite Arrowhead Pharmaceuticals' trouncing the market this year, there's one glaring weakness in its investment thesis at the moment.

Despite Massive Gains This Year, This Biotech Stock Is a Risky Bet

Now that the initial excitement has worn off, investors are correctly responding to the news of a public stock offering.

Here's Why Arrowhead Pharmaceuticals Is Tumbling Today

Counterintuitively, investors are bidding up the share price after the company announced a public stock offering.

Here's Why Arrowhead Pharmaceuticals Is Soaring Today

Innovative Industrial Properties

MercadoLibre

There's gambling, and then there are these businesses with solid prospects you can invest in.

Don't Waste Your Money on Penny Stocks; These 3 Companies Are Better Buys

Arrowhead Pharmaceuticals announced an underwritten offer for 4 million shares late Monday, causing ARWR stock to collapse before the close.

This Highly Rated Biotech Company Just Tumbled 13% On A Public Offering

ACADIA Pharma

China Biologic Products Holdings

Galapagos

Natera

Spark Therapeutics

Zai Lab Ltd.

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

News for Arrowhead Pharmaceuticals Stock (ARWR)